ARTELO BIOSCIENCES

Company snapshot

Artelo Biosciences is a clinical stage company focused on modifying lipid-signaling pathways to improve treatments for people living with cancer (Nasdaq: ARTL)

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 US patent(s) indexed to this assignee profile.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for ARTELO BIOSCIENCES. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for ARTELO BIOSCIENCES.

1. Jun 8, 2026 Clinical update

   ART27.13-100 — Phase 2

2. Jun 21, 2022 Patent grant

   Solid forms of cannabidiol and uses thereof

3. Mar 31, 2020 Patent grant

   Solid forms of cannabidiol and uses thereof

View all clinical trial activity →

• What is ARTELO BIOSCIENCES?

  Artelo Biosciences is a pharma organization headquartered in La Jolla, USA. It trades on NYSE under ticker ARTL. Primary therapeutic focus areas include Cancer Anorexia. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 2 patent record(s) to this entity from publ

• Is ARTELO BIOSCIENCES publicly traded?

  Yes. ARTELO BIOSCIENCES is listed with ticker ARTL on NYSE per SEC EDGAR records linked on this profile.

• What drugs does ARTELO BIOSCIENCES develop or market?

  We link 1 drug profile(s) where ARTELO BIOSCIENCES is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/artelo-biosciences-inc#company-drugs.

• What are the latest developments for ARTELO BIOSCIENCES?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does ARTELO BIOSCIENCES focus on?

  ARTELO BIOSCIENCES focuses on Cancer Anorexia based on our analysis of their pipeline programs and drug development activities.